股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 宜明昂科生物醫藥技術（上海）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01541 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 396,277,305 | RMB | | 1 RMB | | 396,277,305 | | 增加 / 減少 (-) | | | 24,200,000 | | | RMB | | 24,200,000 | | 本月底結存 | | | 420,477,305 | RMB | | 1 RM ...

田博士表示，其对集团的整体发展前景及潜在增长充满信心。在遵守适用法律及监管规定的情况下，不 排除在适当时候进一步增持公司股份。 本文源自：财华网 【财华社讯】宜明昂科-B(01541.HK)早间盘中一度涨逾5%，截至发稿，涨4.37%，报6.68港元。消息面 上，该公司公布，于2025年12月3日，公司执行董事、首席执行官兼董事会董事长田文志博士已在公开 市场购买合共5万股公司H股，每股股份平均价格为约6.6258港元。紧随购买后，田博士于合共约1.16亿 股股份中拥有权益，占公司已发行股本总额26.91%。 ...

本文源自：金融界AI电报 宜明昂科公告，公司执行董事、首席执行官兼董事会董事长田文志博士已于2025年12月3日于公开市场 购买合共50000股公司H股，每股股份平均价格为约6.63港元，占公司已发行股份总数的约0.01%。增持 后，田博士于合共1.16亿股股份中拥有权益，占公司已发行股本总额的26.91%。田博士表示，其对集团 的整体发展前景及潜在增长充满信心，并不排除在适当时候进一步增持公司股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集團」）自願作出，以告知本公司股東及潛在投資者有關本公司執 行董事、首席執行官兼董事會（「董事會」）董事長田文志博士（「田博士」）增持 本公司股份。 董事會獲田博士告知，其已於2025年12月3日於公開市場購買合共50,000股本公 司H股，每股股份平均價格為約6.6258港元，佔本公司已發行股份（「股份」）總 數的約0.01%。緊隨購買後，田博士於合共116,134,090股股份中擁有權益，佔於 本公告日期本公司已發行股本總額的26.91%。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 執行董事、首席執行官兼董事會董事長增持股份 宜明昂科生物醫藥技術（上 ...

Group 1 - YunKang Group (02325.HK) increased by 4.90% [1] - Tongyuan Kang Pharmaceutical-B (02410.HK) rose by 2.73% [1] - Yiming Anke-B (01541.HK) saw a rise of 2.63% [1]

Core Viewpoint - The approval of the clinical research plan for IMM0306 marks a significant advancement in innovative therapies for relapsed/refractory follicular lymphoma, leading to a notable increase in the company's stock price [1] Company Summary - 宜明昂科-B (01541) experienced a stock price increase of over 9%, currently trading at 7.31 HKD with a transaction volume of 10.70 million HKD [1] - The company has received approval from the National Medical Products Administration for the III phase clinical research plan of IMM0306 in combination with lenalidomide for treating relapsed/refractory follicular lymphoma [1] - IMM0306 is the world's first clinical-stage dual-targeting bispecific molecule targeting CD47 and CD20, designed to block the "don't eat me" signal, activating macrophages and NK cells [1] - The drug preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving treatment outcomes [1] - The company holds global intellectual property and commercialization rights for IMM0306 [1]

Core Viewpoint - Yiming Oncology-B (01541) experienced a significant stock increase of over 9%, currently trading at 7.31 HKD, following the approval of its clinical research protocol for IMM0306 by the National Medical Products Administration [1] Group 1: Company Developments - Yiming Oncology announced that it has received approval for the Phase III clinical study of IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma [1] - IMM0306 is the world's first dual-targeting bispecific molecule targeting CD47 and CD20, designed to block the "don't eat me" signal, thereby activating macrophages and NK cells [1] - The drug preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, which could enhance treatment outcomes [1] Group 2: Market Reaction - Following the announcement, Yiming Oncology's stock price rose by 7.98%, with a trading volume of 10.70 million HKD [1]

Core Viewpoint - The approval of the III phase clinical research protocol for IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma marks a significant advancement in innovative therapies for this condition [1] Group 1 - The company has received approval from the National Medical Products Administration (NMPA) for the clinical study [1] - The study focuses on relapsed/refractory follicular lymphoma, indicating a targeted approach to a specific patient population [1] - This development accelerates the progress of innovative treatments in the field of oncology [1]

Core Viewpoint - The approval of the Phase III clinical study protocol for IMM0306 by the National Medical Products Administration marks a significant advancement in innovative therapies for relapsed/refractory follicular lymphoma [1] Group 1: Company Developments - The company has received approval for the Phase III clinical study of IMM0306 in combination with lenalidomide for treating relapsed/refractory follicular lymphoma [1] - IMM0306 is a dual-targeting bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The company holds global intellectual property and commercialization rights for IMM0306 [1] Group 2: Product Mechanism - IMM0306 works by inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, enhancing the interaction between Fc-FcγRIIa and Fc-FcγRIIIa to activate macrophages and NK cells [1] - The molecule preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving treatment outcomes [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the Phase III clinical study of IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma, marking a significant advancement in innovative therapies for this condition [1] Group 1: Product Development - IMM0306 is a dual-targeting bispecific molecule that targets CD47 and CD20, making it the first of its kind to enter clinical stages globally [1] - The mechanism of IMM0306 involves inhibiting the CD47-SIRPα interaction to block the "don't eat me" signal, enhancing the interaction between Fc-FcγRIIa and Fc-FcγRIIIa to activate macrophages and NK cells [1] - The molecule preferentially binds to CD20 rather than CD47, effectively eliminating malignant B cells while minimizing toxicity, thereby improving treatment outcomes [1] Group 2: Intellectual Property and Commercial Rights - The company holds global intellectual property and commercialization rights for IMM0306 as of the date of the announcement [1]